Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Lesser Brian Andrew	2. Date of Event Requiring Statement (MM/DD/YYYY) 11/15/2021	3. Issuer Name and Ticker or Trading Symbol Forma Therapeutics Holdings, Inc. [FMTX]
(Last)        (First)        (Middle) C/O FORMA THERAPEUTICS HOLDINGS, INC., 300 NORTH BEACON STREET, SUITE 501	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) SVP, Commercial Officer /
(Street) WATERTOWN, MA 02472       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	12100 (1)	D
Common Stock	9330 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	11/20/2029	Common Stock	32987	$5.05	D
Stock Option (Right to Buy)	(3)	11/20/2029	Common Stock	17533	$5.05	D
Stock Option (Right to Buy)	(4)	2/11/2030	Common Stock	46756	$5.43	D
Stock Option (Right to Buy)	(5)	6/17/2030	Common Stock	46756	$20.00	D
Stock Option (Right to Buy)	(6)	2/25/2031	Common Stock	36850	$38.61	D

Explanation of Responses:
(1)	These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
(2)	25% of the shares shall vest on the first anniversary of September 23, 2019, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date.
(3)	25% of the shares shall vest on the first anniversary of November 21, 2019, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date.
(4)	25% of the shares shall vest on the first anniversary of February 12, 2020, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date.
(5)	25% of the shares shall vest on the first anniversary of June 18, 2020, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date.
(6)	25% of the shares shall vest on the first anniversary of February 22, 2021, and the remaining 75% of such shares shall vest in thirty-six (36) equal monthly installments; provided that the Reporting Person remains continuously engaged by the Company on each such date.

Remarks: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Lesser Brian Andrew C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET, SUITE 501 WATERTOWN, MA 02472			SVP, Commercial Officer

Signatures
/s/ Jeannette Potts, as Attorney-in-Fact		11/19/2021
**Signature of Reporting Person		Date